Win Min Han

clinical/epi research @KirbyInstitute @HIVNAT

[Clinical Infectious Diseases @CIDJournal]

Early Antiretroviral Therapy Not Associated With Higher Cryptococcal Meningitis Mortality in People With Human Immunodeficiency Virus in High-Income Countries: An International Collaborative Cohort Study

🔓 Open Access
https://t.co/LoWaqJiFAh

[Clinical Infectious Diseases @CIDJournal]

Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis with liver fibrosis as predictors of new-onset Diabetes Mellitus in People living with HIV: A Longitudinal Cohort Study

✅ Just Accepted
https://t.co/TSIE9yG8ZL

[Paul Sax @PaulSaxMD]

Some thoughts on the biggest news out of #IAS2023, which was undoubtedly the @reprievetrial -- and what it implies about the staggering success of HIV treatment that the most important HIV clinical trial in years involves a *statin*!
Think about that ...
https://t.co/fDDUU3ieNn

[Win Min Han @WinMinHan16]

In this longitudinal cohort study, people living w/ HIV with baseline NAFLD or those who developed NAFLD during FU had an increased new-onset DM risk over a median 4 yrs FU. TAF, but not InSTI, was associated with elevated risk of incident NAFLD or NASH. https://t.co/VeaW7UeCII

[NEJM @NEJM]

Presented at #IAS2023: In a trial involving participants with HIV infection receiving antiretroviral therapy, the use of pitavastatin resulted in a lower risk of a major adverse cardiac event than placebo at a median of 5.1 years. Read the full REPRIEVE trial results:

[The Lancet HIV @TheLancetHIV]

Results from the ALLIANCE trial are in; bictegravir, emtricitabine, and tenofovir alafenamide show non-inferiority to dolutegravir, emtricitabine, and tenofovir disoproxil fumarate in adults with HIV-1 and HBV coinfection.
https://t.co/elZQraWEzR

[The Lancet Healthy Longevity @LancetLongevity]

New: Epigenetic ageing accelerates before antiretroviral therapy and decelerates after viral suppression in people with HIV in Switzerland: a longitudinal study over 17 years by Isabella Schoepf @unibern@UniBasel_en and colleagues https://t.co/z4bNTHTdHF #OpenAccess

[Sergio Serrano Villar - serranovillar.bsky.social @serranovillar]

Check it out!

>10 years of research in the field of the CD4/CD8 ratio as a prognostic factor during treated HIV.

What we know, what we don't know, and future directions reviewed here 👇

https://t.co/YOoaO7qbKr

@OUPMedicine @ciberinfec @riscomunica @SEIMC_

[NEJM @NEJM]

#CROI2023: Treatment for tuberculosis, a leading cause of death worldwide, typically involves 6 months of continuous therapy. In the TRUNCATE-TB trial, a strategy involving shorter initial treatment was noninferior to standard treatment. https://t.co/oeIlHaPZ41

[Annette Sohn @annettesohnBKK]

New @unaids data on #HIV treatment coverage for pregnant women in @ASEAN are heartbreaking 💔

Only 15% in Indonesia and the Philippines; fell from 72% to 18% in Myanmar during their civil war.

The Asia-Pacific is now worse than sub-Saharan Africa.

@ProfAdeeba @EamonnMurphy63

[IAC - the International AIDS Conference @AIDS_conference]

A Phase 3, multi-country ALLIANCE study comparing B/F/TAF and DTG+F/TDF for treatment of adults living with both HIV and HBV found that B/F/TAF resulted in superior HBV DNA suppression and significantly more HBeAg seroconversion. #AIDS2022

[Annette Sohn @annettesohnBKK]

Thanks to @JAMANetwork for highlighting our study showing only 59% of children and 65% of adults w/ #HIV in @iedeaglobal had viral suppression after 3 yrs of treatment. #HIVisnotover

Work led by PhD student @WinMinHan16 of @KirbyInstitute.
@HIVNAT @NIAIDNews

[Keri N Althoff @kerinalthoff]

NEW: Breakthrough SARS-CoV-2 infections after vaccination were rare in both people with & without #HIV between Jan - Sept 2021.

Preprint here: https://t.co/OCgatlL5a9

[The Lancet HIV @TheLancetHIV]

New: Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries by Win Min Han and colleagues https://t.co/KkMeqzkfrL

[Win Min Han @WinMinHan16]

The analysis also adjusted for missing VL measurements from people being lost to care. Although estimated #HIV viral suppression rates were approaching the 95% target in adults in several regions, viral suppression among children/adolescents was much further away from the target.

[Annette Sohn @annettesohnBKK]

.@iedeaglobal paper in @TheLancetHIV on #HIV viral load suppression in 31 countries, by @WinMinHan16 of @HIVNAT & PhD student of @KirbyInstitute.
Suppression at 3 yrs of ART: 59% in children/adolescents, 65% in adults.

We are still far off from 90-90-90.
https://t.co/JRD1gO3kQk